Resultats globals: 3 registres trobats en 0.02 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
7 p, 1.3 MB Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer / Melisi, Davide (University of Verona, Piazzale Ludovico Antonio Scuro) ; Garcia-Carbonero, Rocio (Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), UCM, CNIO, CIBERONC, Madrid, Spain) ; Macarulla, Teresa (VHIO) ; Pezet, Denis (Centre Hospitalier Universitaire) ; Deplanque, Gael (Hôpital Riviera-Chablais) ; Fuchs, Martin (Klinikum Bogenhausen, Städtisches Klinikum München GmbH, Englschalkinger Road 77, 81925 Munich, Germany) ; Trojan, Jorg (Goethe University Medical Center) ; Oettle, Helmut (Onkologische und Hämatologische Schwerpunktpraxis, Friedrichshafen, Germany) ; Kozloff, Mark (Ingalls Memorial Hospital) ; Cleverly, Ann (Eli Lilly and Company, Erl Wood Manor, Windlesham) ; Smith, Claire (formerly of Eli Lilly and Company) ; Estrem, Shawn T. (Eli Lilly and Company, Lilly Corporate Center) ; Gueorguieva, Ivelina (Eli Lilly and Company, Erl Wood Manor, Windlesham) ; Lahn, Michael M. F. (Wisconsin Ave., #8008, Bethesda, MD 20815 USA) ; Blunt, Al (Advaxis, Inc) ; Benhadji, Karim A. (Eli Lilly and Company) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina)
Galunisertib is the first-in-class, first-in-human, oral small-molecule type I transforming growth factor-beta receptor (ALK5) serine/threonine kinase inhibitor to enter clinical development. The effect of galunisertib vs. [...]
2018 - 10.1038/s41416-018-0246-z
British Journal of Cancer, Vol. 119 (october 2018) , p. 1208-1214  
2.
7 p, 770.6 KB Proxies of quality of life in metastatic colorectal cancer : analyses in the RECOURSE trial / Van Cutsem, Eric (University Hospitals Leuven and KU Leuven) ; Falcone, Alfredo (Azienda Ospedaliero-Universitaria Pisana) ; García Carbonero, Rocio (Hospital Universitario 12 de Octubre/i+12) ; Komatsu, Yoshito (Hokkaido University Hospital) ; Pastorino, Alessandro (IRCCS AOU San Martino IST) ; Peeters, Marc (Antwerp University Hospital) ; Shimada, Yasuhiro (National Cancer Center Hospital) ; Yamazaki, Kentaro (Shizuoka Cancer Center) ; Yoshino, Takayuki (National Cancer Center Hospital East) ; Zaniboni, Alberto (Fondazione Poliambulanza) ; Amellal, Nadia (Institut de Recherches Servier) ; Kanehisa, Akira (Institut de Recherches Servier) ; Winkler, Robert (Taiho Oncology) ; Makris, Lukas (Taiho Oncology) ; Mayer, Robert J (Dana-Farber Cancer Institute) ; Ohtsu, Atsushi (National Cancer Center Hospital East) ; Taberneroo, J (Universitat Autònoma de Barcelona. Deaprtament de Medicina)
In the pivotal phase III, randomised, double-blind, placebo-controlled RECOURSE study, treatment with trifluridine/tipiracil was well tolerated and associated with prolonged progression-free and overall survival in patients with metastatic colorectal cancer (mCRC). [...]
2017 - 10.1136/esmoopen-2017-000261
ESMO Open, Vol. 2 (november 2017)  
3.
9 p, 1023.2 KB Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain : results of a subgroup analysis of the phase 3 RECOURSE trial / Longo Muñoz, Federico (Hospital Universitario Ramón y Cajal) ; Argilés Martínez, Guillem (Hospital Universitari Vall d'Hebron) ; Taberneroo, J (Hospital Universitari Vall d'Hebron) ; Cervantes, A. (Universitat de València) ; Grávalos, Cristina (Hospital Universitario Doce de Octubre) ; Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Gil Calle, S. (Hospital Carlos Haya) ; Mizuguchi, Hirokazu (Taiho Oncology) ; Carrato, Alfredo (Hospital Universitario Ramón y Cajal) ; Limón, María Luisa (Hospital Universitario Virgen del Rocío) ; García Carbonero, Rocio (Hospital Universitario Doce de Octubre) ; Universitat Autònoma de Barcelona
TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase 3 RECOURSE trial. [...]
2017 - 10.1007/s12094-016-1528-7
Clinical & Translational Oncology, Vol. 19, Issue 2 (February 2017) , p. 227-235  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.